it is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. it has been described in literature since at least the late 1980s as a potential treatment for iron deficiency.  it was granted FDA Approval on 25 July 2019. 
